Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mission Bio Launches First Automated Custom Panel Designer for Mouse Genomes and CRISPR Editing to Accelerate Breakthroughs in Cancer Research
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA
Cibus Achieves Critical Milestones for Two New Gene-Edited Traits that Increase Productivity for Rice Farmers